ONO PHARMACEUTICAL CO.,LTD.

December 24, 2019

Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This information is intended to notify the press release issued on December 23, 2019 (ET) by Karyopharm Therapeutics Inc. Please click http://investors.karyopharm.com/press-releases for the original press release.

First paragraph extracted from the original press release:

(NEWTON, Mass., December 23, 2019) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation, including CAR-T (chimeric antigen receptor modified T cell) therapy. XPOVIO has received both Orphan Drug and Fast Track designations from the FDA for this indication.

About the Ono and Karyopharm Collaboration

In October 2017, Ono Pharmaceutical Co., Ltd. concluded an exclusive license agreement with Karyopharm Therapeutics Inc. for the development and commercialization of Selinexor, their first-in-class oral XPO1 (Exportin 1) inhibitor, and Eltanexor/KPT-8602, a second-generation oral XPO1 inhibitor, for all oncology indications exclusively in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries.

About the Development Status of Selinexor (ONO-7705) in Japan

Selinexor (ONO-7705) is now under Phase I study in Japan for the treatment of multiple myeloma and non-Hodgkin lymphoma.

Contacts:
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp